Benzinga | Jun 21, 2021 07:10AM EDT

GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab

-- Analysis of final Day 29 data from COMET-ICE confirms sotrovimab significantly reduces

hospitalization and risk of death in adults with mild-to-moderate COVID-19 who are at high risk

of progression to severe disease --

-- U.S. National Institutes of Health (NIH) COVID-19 Treatment Guidelines

updated to recommend use of sotrovimab --

-- Further research initiated to evaluate intramuscular administration of sotrovimab for the

early treatment of mild-to-moderate COVID-19 in high-risk patients in a Phase 3 study --